Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2024
Genelux (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, has announced its participation in BTIG's Virtual Biotechnology Conference 2024. The company's President, CEO, and Chairman, Thomas Zindrick, will engage in a fireside chat with Kaveri Pohlman, PhD, Director and BTIG Biotechnology Analyst. The discussion is scheduled for Tuesday, August 6, 2024, at 12:00 p.m. ET.
During the chat, Zindrick will provide insights into Genelux's clinical-stage programs, recent announcements, and upcoming milestones. This event presents an opportunity for investors and industry professionals to gain valuable information about Genelux's progress and future plans in the immuno-oncology field.
Genelux (NASDAQ: GNLX), un'azienda di immuno-oncologia in fase clinica avanzata, ha annunciato la sua partecipazione alla Virtual Biotechnology Conference 2024 di BTIG. Il presidente, CEO e chairman dell'azienda, Thomas Zindrick, parteciperà a una chiacchierata informale con Kaveri Pohlman, PhD, direttore e analista di biotecnologie di BTIG. La discussione è programmata per martedì 6 agosto 2024, alle 12:00 p.m. ET.
Durante la chat, Zindrick fornirà approfondimenti sui programmi in fase clinica di Genelux, sugli annunci recenti e sui traguardi futuri. Questo evento rappresenta un'opportunità per gli investitori e i professionisti del settore di ottenere informazioni preziose sui progressi e i piani futuri di Genelux nel campo dell'immuno-oncologia.
Genelux (NASDAQ: GNLX), una empresa de inmuno-oncología en etapa clínica avanzada, ha anunciado su participación en la Virtual Biotechnology Conference 2024 de BTIG. El presidente, CEO y presidente de la empresa, Thomas Zindrick, participará en una charla informal con Kaveri Pohlman, PhD, directora y analista de biotecnología de BTIG. La discusión está programada para el martes 6 de agosto de 2024 a las 12:00 p.m. ET.
Durante la charla, Zindrick ofrecerá información sobre los programas en etapa clínica de Genelux, anuncios recientes y logros futuros. Este evento representa una oportunidad para que los inversores y profesionales de la industria obtengan información valiosa sobre los avances y planes futuros de Genelux en el campo de la inmuno-oncología.
Genelux (NASDAQ: GNLX)은 임상 단계의 면역항암학 회사로서 BTIG의 2024년 가상 생명공학 회의에 참석한다고 발표했습니다. 회사의 대통령이자 CEO이자 회장인 Thomas Zindrick는 Kaveri Pohlman, PhD와 비공식 대화를 나눌 예정입니다. Pohlman은 BTIG의 생명공학 분석가입니다. 이 논의는 2024년 8월 6일 화요일 오후 12:00 (ET)로 예정되어 있습니다.
채팅 중 Zindrick은 Genelux의 임상 단계 프로그램, 최근 발표사항 및 앞으로의 이정표에 대한 통찰력을 제공할 것입니다. 이 행사는 투자자와 업계 전문가들에게 Genelux의 진전 및 면역항암학 분야의 미래 계획에 대한 귀중한 정보를 얻을 수 있는 기회를 제공합니다.
Genelux (NASDAQ: GNLX), une entreprise d'immuno-oncologie en phase clinique avancée, a annoncé sa participation à la Virtual Biotechnology Conference 2024 de BTIG. Le président, PDG et président de la société, Thomas Zindrick, participera à une discussion informelle avec Kaveri Pohlman, PhD, directrice et analyste en biotechnologie chez BTIG. La discussion est prévue pour le mardi 6 août 2024 à 12h00 ET.
Lors de cet échange, Zindrick fournira des informations sur les programmes en phase clinique de Genelux, les annonces récentes et les jalons à venir. Cet événement représente une occasion pour les investisseurs et les professionnels du secteur d'obtenir des informations précieuses sur les progrès et les projets futurs de Genelux dans le domaine de l'immuno-oncologie.
Genelux (NASDAQ: GNLX), ein Unternehmen für Immunonkologie in der späten klinischen Phase, hat seine Teilnahme an der Virtuellen Biotechnologie-Konferenz 2024 von BTIG angekündigt. Der Präsident, CEO und Vorsitzende des Unternehmens, Thomas Zindrick, wird sich in einem informellen Gespräch mit Kaveri Pohlman, PhD, Direktorin und Biotechnologie-Analystin bei BTIG, austauschen. Die Diskussion ist für Dienstag, den 6. August 2024, um 12:00 Uhr ET angesetzt.
Während des Gesprächs wird Zindrick Einblicke in die klinischen Programme von Genelux, aktuelle Ankündigungen und bevorstehende Meilensteine geben. Diese Veranstaltung bietet Investoren und Fachleuten der Branche die Möglichkeit, wertvolle Informationen über den Fortschritt und die zukünftigen Pläne von Genelux im Bereich der Immunonkologie zu erhalten.
- None.
- None.
WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at BTIG’s Virtual Biotechnology Conference 2024.
The conversation with Kaveri Pohlman, PhD, Director and BTIG Biotechnology Analyst, is scheduled to begin at 12:00 p.m. ET on Tuesday, August 6, 2024.
About Genelux Corporation
Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer. The core of Genelux' discovery and development efforts revolves around its’ proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit www.genelux.com and follow us on Twitter @Genelux_Corp and on LinkedIn.
Investor and Media Contacts
Ankit Bhargava, MD
Allele Communications, LLC
genelux@allelecomms.com
Source: Genelux Corporation
FAQ
When is Genelux (GNLX) participating in BTIG's Virtual Biotechnology Conference 2024?
Who will represent Genelux (GNLX) at the BTIG Virtual Biotechnology Conference 2024?
What topics will Genelux (GNLX) discuss at the BTIG conference?
Who will be interviewing the Genelux (GNLX) representative at the BTIG conference?
